Institution Logo

Sylvester Comprehensive Cancer Center at University of Miami Health System

Kidney Cancer Program

Primary Address

1475 NW 12th Ave
Miami, FL, 33136
(305) 243-5302
Appointments: (305) 243-5302
Program Website

Satellite Locations

Sylvester Comprehensive Cancer Center at Solé Mia

2111 Sole Mia Way North Miami, FL 33181

Sylvester Comprehensive Cancer Center Lennar Foundation Medical Center

5555 Ponce de Leon Blvd, 3rd Floor Coral Gables, FL 33146

Sylvester Comprehensive Cancer Center Plantation

8100 SW 10th St 1st Floor Plantation, FL 33324

Sylvester Comprehensive Cancer Center at Deerfield Beach

1192 E Newport Center Dr Deerfield Beach, FL 33442

Sylvester Comprehensive Cancer Center

Sylvester Comprehensive Cancer Center

Key Contacts

Medical Oncology:
Dr. Jaime Merchan – Professor of Medicine
Urologic Surgery Lead:
Dr. Mark Gonzalgo MD., PhD – Professor of Urology
Radiation Oncology Lead:
Dr. Matthew Abramowitz – Associate Professor, Radiation Oncology
Patient Navigator & Appointments:
Call (305) 243-5302

Volume

Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.

Kidney Cancer Surgery Volume

Very High

Clear Cell Kidney Cancer Diagnosis Volume

High

Non–Clear Cell Kidney Cancer Diagnosis Volume

Very High

Clinical Trial Participation Volume

Very High

Radiation & Ablation Procedure Volume

High

About these ratings

Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.

Types of Services Offered

Clinical Trials End of Life Services Genetic Counseling Infusion Center Integrated Multidisciplinary Clinic Integrative Oncology Molecular Testing Oncology Urgent Care Clinic Patient Case Discussions / Tumor Boards Precision Medicine Supportive Care / Pain Clinics Survivorship Clinics Interventional Radiology Medical Oncology Pain Management Palliative Care Pathology Radiation Oncology Radiology Urologic Surgery

Kidney Cancer Types & Expertise

Chromophobe RCC Clear Cell RCC Collecting Duct RCC FH-deficient RCC Papillary RCC Renal Medullary Carcinoma Sarcomatoid Translocation RCC Tuberous Sclerosis–associated RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Pediatric (diagnosed under age 18) Pregnancy Solitary Kidney Young Adult (age 18-50)

Special Programs, Recognitions & Outcomes

American College of Surgeons Accredited Cancer Program Government-Funded Research NCI Designated Cancer Center

Research Programs

Clinical Multi-Institutional Collaboration Population-Based Research Lab Translational

Multi-Institutional Collaborations

University of Miami Miller School of Medicine
Precision Oncology Alliance (Caris Life Sciences network)
National Cancer Institute-sponsored multicenter clinical trial networks

Patient Resources & Support Services

Art Therapy Fertility Preservation Counseling Financial Navigators Interpreter Services Lodging / Long-Term Housing Lymphedema Therapy Music Therapy Nurse Navigators Nutrition Services / Dietician Occupational Therapy On-site Dispensing / Pharmacy Parking Assistance (valet or concierge) Pastoral / Spiritual Care Patient Navigators Peer Support Options Physical Therapy Psychiatrists / Psychologists Social Workers / Counselors Transportation Service Wellness Center

Insurance Carriers

Accepted

  • Aetna
  • AvMed
  • Blue Cross Blue Shield / Florida Blue
  • Cigna
  • Humana
  • Medicaid
  • Medicare
  • Medicare Advantage (participating plans)
  • Molina Healthcare
  • Multiplan/PHCS
  • Preferred Care Partners
  • Tricare
  • UnitedHealthcare
  • UMR
  • WellMed
  • Workers' Compensation
  • CHAMPUS
  • Ambetter
  • AmeriHealth
  • Amerigroup
  • Anthem Blue Cross Blue Shield
  • Alignment Health
  • All Savers
  • Allegiance
  • Alliant Health Plans
  • EmblemHealth
  • Curative
  • APWU Health Plan
  • 1199SEIU Benefit Funds
  • AARP Medicare plans (participating carriers)

Open Clinical Trials

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.<br /> <br /> In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of:<br /> <br /> * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and<br /> * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab in participants with ccRCC in the dose expansion stage

Request an Appointment